MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

Strona główna・Stock List・Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Closed

SectorHealthcare

339.06 1.82

Buy Sell

Overview

Share price change

24h

Current

Min

329.96

Max

343.01

Key metrics
By Trading Economics
Income	-65M 186M
Sales	-152M 1.1B
P/E Sector Avg	141.777 66.418
EPS	1.25
Profit margin	16.993
Employees	2,500
EBITDA	-152M 145M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+35.88% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	1.5B 44B
Previous open	337.24
Previous close	339.06

News Sentiment

By Acuity

50%

154 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

256.565 / 269.81 Support & Resistance

Alnylam Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

13 kwi 2026, 23:25 UTC

Major News Events

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

13 kwi 2026, 22:45 UTC

Major News Events

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

13 kwi 2026, 18:03 UTC

Earnings

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

13 kwi 2026, 23:58 UTC

Earnings

Review & Preview: Earnings Time -- Barrons.com

13 kwi 2026, 23:49 UTC

Market Talk

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

13 kwi 2026, 23:33 UTC

Market Talk

Major News Events

Gold Edges Higher Amid Dollar Weakness -- Market Talk

13 kwi 2026, 23:20 UTC

Market Talk

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

13 kwi 2026, 23:01 UTC

Earnings

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

13 kwi 2026, 23:01 UTC

Earnings

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

13 kwi 2026, 23:01 UTC

Earnings

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

13 kwi 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

13 kwi 2026, 21:53 UTC

Earnings

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

13 kwi 2026, 21:53 UTC

Earnings

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

13 kwi 2026, 21:53 UTC

Earnings

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

13 kwi 2026, 21:53 UTC

Earnings

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

13 kwi 2026, 21:26 UTC

Major News Events

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

13 kwi 2026, 21:23 UTC

Earnings

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

13 kwi 2026, 21:16 UTC

Earnings

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

13 kwi 2026, 20:50 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

13 kwi 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

13 kwi 2026, 20:34 UTC

Earnings

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

13 kwi 2026, 20:34 UTC

Earnings

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

13 kwi 2026, 20:34 UTC

Earnings

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

13 kwi 2026, 19:59 UTC

Market Talk

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

13 kwi 2026, 19:50 UTC

Market Talk

Major News Events

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

13 kwi 2026, 19:27 UTC

Market Talk

Major News Events

Correction to Precious Metals Market Talk on April 9

13 kwi 2026, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

13 kwi 2026, 18:59 UTC

Market Talk

Major News Events

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

13 kwi 2026, 18:59 UTC

Market Talk

Major News Events

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

13 kwi 2026, 18:43 UTC

Market Talk

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Peer Comparison

Price change

Alnylam Pharmaceuticals Inc Forecast

Price Target

By TipRanks

35.88% upside

12 Months Forecast

Average 452.47 USD 35.88%

High 549 USD

Low 330 USD

Based on 20 Wall Street analysts offering 12 month price targets forAlnylam Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

20 ratings

Buy

Hold

Sell

Based on 20 analysts giving stock ratings to Alnylam Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

256.565 / 269.81Support & Resistance

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

154 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.